Provided by Tiger Trade Technology Pte. Ltd.

Personalis

8.06
+0.64008.63%
Post-market: 8.03-0.0250-0.31%19:32 EST
Volume:1.41M
Turnover:11.28M
Market Cap:714.29M
PE:-9.20
High:8.25
Open:7.85
Low:7.58
Close:7.42
52wk High:11.50
52wk Low:2.83
Shares:88.68M
Float Shares:52.59M
Volume Ratio:1.18
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8755
EPS(LYR):-1.3719
ROE:-43.69%
ROA:-20.95%
PB:4.17
PE(LYR):-5.87

Loading ...

Personalis announces publication of new study on NeXT Personal

TIPRANKS
·
Feb 02

Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Response Across Multiple Cancers

Reuters
·
Feb 02

Personalis Inc. to Attend BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Reuters
·
Jan 29

Personalis Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares

Reuters
·
Jan 24

Stock Track | Personalis (PSNL) Soars 5.02% Intraday After Receiving Buy Rating from Lake Street

Stock Track
·
Jan 14

Personalis (PSNL) Receives a Buy from Lake Street

TIPRANKS
·
Jan 13

Personalis: Strengthened Balance Sheet and NeXT Personal Growth Underpin Reiterated Buy Rating and $12 Target

TIPRANKS
·
Jan 09

Personalis Price Target Maintained With a $12.00/Share by BTIG

Dow Jones
·
Jan 09

Personalis Stock Falls on Preliminary 4Q Results

Dow Jones
·
Jan 09

Personalis Preliminary Q4 Revenue Within Analyst Range

MT Newswires Live
·
Jan 08

BRIEF-Personalis Reports Select Preliminary Fourth Quarter And Full Year 2025 Results

Reuters
·
Jan 08

GUIDANCE: (PSNL) Personalis Expects Fiscal Q4 Revenue Range $17M to $18M, vs. FactSet Est of $17.6M

MT Newswires Live
·
Jan 08

Personalis Inc - Preliminary Q4 Revenue of $17-$18 Mln

THOMSON REUTERS
·
Jan 08

Press Release: Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dow Jones
·
Jan 08

BRIEF-Personalis Announces New Publication Applying Ultrasensitive CtDNA Testing

Reuters
·
Dec 17, 2025

Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors

Reuters
·
Dec 17, 2025

Personalis Announces New Publication Applying Ultrasensitive Ctdna Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

THOMSON REUTERS
·
Dec 17, 2025

Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study

Reuters
·
Dec 11, 2025

Personalis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Dec 03, 2025